An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

NCT05832255 | Suspended Phase 2

• 1 other identifier: 22NMCFN01
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS. Current therapies, including pharmaceutical and behavioural interventions, offer a patchwork of solutions that have limited efficacy and high toxicity. The current study aims to examine psilocybin as a safe treatment alternative with the ability to improve markers of cognition, communication, mood, behavior as well as markers of neuroinflammation, serotonin levels in exosomes, and neuroplasticity at sub-hallucinogenic doses (microdosing). The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.

Conditions

Fragile X Syndrome; Behavior; Cognitive Dysfunction

Keywords

Fragile X Syndrome; Behavior; Cognitive Symptoms; Psilocybin; Microdose

Outcome Measures

Primary Outcomes (8)

• Retention rate associated with 10 participants progressing to study completion.

  Study completion is defined as completing the 28-day treatment period and the final in-clinic study visit.

  baseline to day 28

• Compliance with study dosing regimen as measured by the Visual Analogue Scale for Dosing (VAS-D).

  Participants will be monitored for compliance using electronic compliance checks via the remote patient reported outcomes system through recording consumption in the treatment diary. Participants and caregivers will receive daily notifications via their preferred format (i.e., email, text) during agreed upon dosage windows. Notification will include a reminder to complete a post-dosage Visual Analogue Scale for Dosing (VAS-D) to monitor for any side effects which can be submitted electronically. Failure to complete the VAS-D within the day of dosing will trigger a call from study personnel to the participant in order to do a compliance check. Study personnel will note any deviations and all points of contact with participants regarding compliance checks.

  baseline to day 28

• Compliance with study dosing regimen as measured by the quantity of unused investigational product returned to the study clinic.

  baseline to day 28

• Adherence with completion of diaries monitoring participant and caregiver reported outcomes.

  Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., diaries) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver diaries divided by the number of diaries expected to be completed.

  baseline to day 28

• Adherence with completion of questionnaires monitoring participant and caregiver reported outcomes.

  Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., questionnaires) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver questionnaires divided by the number of questionnaires expected to be completed.

  baseline to day 28

• The number of late entries for diaries monitoring patient reported and caregiver reported outcomes.

  baseline to day 28

• The number of late entries for questionnaires monitoring patient reported and caregiver reported outcomes.

  baseline to day 28

• Satisfaction with study questionnaire.

  baseline to day 28

Secondary Outcomes (19)

• Change from baseline in standardized measures of behavioral rigidity using the ratings of repetitive and stereotyped behaviors from the revised Repetitive Behavior Scale (RBS-R).

  baseline, day 15, day 28

• Change in standardized measures of empathy using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).

  baseline, day 15, day 28

• Change in standardized measures of empathy using the overall score on the Multifaceted Empathy Test (MET).

  baseline, day 15, day 28

• Change in standardized measures of expressive and receptive language skills using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).

  baseline, day 15, day 28

• Change in standardized measures of expressive and receptive language skills using the overall score on the Multifaceted Empathy Test (MET).

  baseline, day 15, day 28

Other Outcomes (8)

• To improve diagnostic phenotyping of FXS through analysis of biomarkers using buccal swab and saliva samples.

  baseline, day 15, day 28

• To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using saliva samples from baseline to study end.

  baseline, day 15, day 28

• To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using buccal swabs from baseline to study end.

  baseline, day 15, day 28

Study Arms (1)

Psilocybin, 1.5 mg

EXPERIMENTAL

Participants will take one capsule containing 1.5 mg psilocybin with a glass of water every other day for a period of 28 days. Dosing schedule will be same for all participants with the drug taken at days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and no treatment taken on alternating days. No subject shall be provided with more than five capsules (7.5mg psilocybin) at any one time to prevent diversion to the illicit market. If a dose is missed, participants are instructed to skip that dose and continue with their regularly scheduled medications. Participants are not to take \>1 capsule per day.

Drug: Psilocybin, 1.5 mg

Interventions

Psilocybin, 1.5 mg DRUG

Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.

Psilocybin, 1.5 mg

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• to 50 years of age
• BMI \> 18.3
• Diagnosis of Fragile X syndrome with a molecular genetic confirmation of the full FMR1 mutation (\>200 CGG repeats) or the other loss of function mutations of the FMR1 gene (SNVs and deletions of the gene) based on evidence provided by caregiver from prior assessment
• IQ between 40 and 85 points as reported by caregiver based on prior assessment
• Subject has the ability to understand and provides voluntary, written, informed consent to participate in the study
• Or,
• For subjects who are not their own legal guardian, or do not have the capacity to provide informed consent, subject's parent/legal authorized guardian is able to understand and sign an informed consent form to participate in the study.
• Caregiver (parent, guardian, or other legally authorized representative) who is willing to participate in the whole study and provides informed consent
• Subject is able to swallow tablets and capsules
• Individual is not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
• Or,
• Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
• Abstinence (only in cases when abstinence is the usual and customary form of birth control for the participant)
• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
• Double-barrier method

You may not qualify if:

• Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
• Allergy, sensitivity, or intolerance to the investigational product's active or inactive ingredients
• Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, N-methyl-D-aspartate (NMDAR) antagonists, antipsychotics, and stimulants
• Urine drug test containing non-prescribed drugs of abuse (non-prescribed opioids, benzodiazepines, amphetamines, phencyclidine, cocaine) at screening and day of first treatment. Urine cannabinoid concentrations \>50 ng/ml will suggest heavy marijuana use and will be a threshold for excluding potential subjects
• Having uncontrolled hypertension defined as an average systolic blood pressure ≥140 mmHg or an average diastolic blood pressure ≥90 mmHg, with at least 4 BP assessments completed.
• Have any of the following cardiovascular conditions: coronary artery disease, congenital long QT (time from the start of the Q wave to the end of the T wave) syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition
• Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
• Subjects with a history of seizure disorder except those who are currently receiving treatment with anti-epileptics and have been seizure-free for 3 months preceding screening or have been seizure-free for 3 years if not currently receiving anti-epileptics.
• Reported history of moderate to severe hepatic impairment
• Type I or insulin-dependent Type II diabetes
• Meet DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features, or Bipolar I or Bipolar II Disorder
• Meet DSM-5 criteria for a moderate or severe alcohol or drug use disorder in the past 12 months
• Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study
• Medical illness based on physical examination, ECG and routine testing that may complicate cardiovascular safety or drug metabolism or excretion, such as metabolic disease, severe cardiac disease, or kidney or liver failure as assessed by the QI. QI assessments will be based on clinical history provided by caregivers and/or physicians. Any participant requiring further assessment will be referred accordingly or excluded by the QI on a case-by-case basis.\*
• Current or history of any significant diseases of the gastrointestinal tract, exceptions to be determined by the QI

Sponsors & Collaborators

• Nova Mentis Life Science Corp: lead
• KGK Science Inc.: collaborator

Study Sites (1)

KGK Science Inc.

London, Ontario, N6B 3L1, Canada

Location

MeSH Terms

Conditions

Fragile X Syndrome; Behavior; Cognitive Dysfunction; Neurobehavioral Manifestations

Interventions

Psilocybin

Condition Hierarchy (Ancestors)

X-Linked Intellectual Disability; Intellectual Disability; Neurologic Manifestations; Nervous System Diseases; Sex Chromosome Disorders; Chromosome Disorders; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Heredodegenerative Disorders, Nervous System; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Indole Alkaloids; Alkaloids; Heterocyclic Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Tryptamines; Indolizidines; Indolizines

Study Officials

• David Crowley, MD

  KGK Science Inc.

  PRINCIPAL INVESTIGATOR

• Marvin Hausman, MD

  Nova Mentis Life Science Corp

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 8, 2023
• First Posted: April 27, 2023
• Study Start: March 28, 2023
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: May 8, 2024

Record last verified: 2024-05

Locations

CA (1)